Table 4.
Measures of diagnostic accuracy of FebriDx MxA for identification of COVID-19, according to duration of illness.
| n/n | ≤7 days of symptoms n = 129 Value (95% CI) |
n/n | >7 days of symptoms n = 86 Value (95% CI) |
|
|---|---|---|---|---|
| Median (IQR) duration, days | 4 (1 to 6) | 14 (8 to 14) | ||
| Prevalence of COVID-19 | 52/129 | 40 (32 to 49) | 53/86 | 62 (51 to 71) |
| Sensitivity | 49/52 | 94 (84 to 98) | 48/53 | 91 (80 to 96) |
| Specificity | 65/77 | 84 (75 to 91) | 29/33 | 88 (73 to 95) |
| Positive predictive value | 49/61 | 80 (69 to 88) | 48/52 | 92 (82 to 97) |
| Negative predictive value | 65/68 | 96 (88 to 99) | 29/34 | 85 (71 to 93) |
| Positive likelihood ratio | 6.05 (3.58 to 10.0) | 7.47 (2.96 to 19.0) | ||
| Negative likelihood ratio | 0.07 (0.02 to 0.21) | 0.11 (0.5 to 0.25) |
IQR=Interquartile range, CI=Confidence interval.